Metabolic research
Retatrutide Research review
A selected obesity trial shows a weight-loss signal. That finding does not validate products sold outside clinical development.
Human phase 2 trialSources checked September 12, 2026
01 / Context first
The research setting
Adults with obesity or overweight and a weight-related condition in a randomized placebo-controlled trial.
02 / The findings
What the sources found
- Participants assigned retatrutide lost more weight than those assigned placebo in the selected trial.
- Gastrointestinal effects and increased heart rate were reported.
03 / The open questions
Where the evidence stops
- This review covers the cited trial, not a complete account of the development program.
- Trial findings do not verify the contents or safety of an online vial.
04 / Safety context
Before drawing conclusions
FDA states that retatrutide is not a component of an approved drug and cannot be used in compounding under federal law.
These reviews do not provide instructions for self-treatment. Discuss personal medical questions with a qualified clinician.
05 / Go to the originals
Read the sources
Inspect the original research and regulatory context behind this review.
- Original research — PubMed abstractTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. ↗
- FDA safety informationFDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss ↗
Sources checked September 12, 2026. Next editorial review due December 11, 2026.
Read the review methodology →